Clinical pharmacology of beta-adrenoceptor antagonism in angina pectoris: an overview
Related Experiment Video
Updated: Oct 9, 2026
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Abstract:
Beta antagonists competitively block beta 1-adrenoceptors that mediate both the rate and force of myocardial contraction. Their precise mechanism of anti-anginal action is uncertain. A reduction in oxygen demand may relative pain and improve effort tolerance. Alternatively inhibition of the adrenergic drive to contraction may offset the increased ventricular wall tension due to incomplete relaxation. Partial agonist activity in a beta-antagonist does not influence efficacy nor protect against airflow obstruction. Membrane stabilising activity is clinically trivial. Cardioselectivity makes airflow obstruction less likely at low but not at high blood concentrations of drug. Alpha-receptor antagonism may also prevent broncho-constriction; it has not been assessed in coronary vasospasm. The dosage and choice of drugs are based on pharmaco-kinetic and dynamic data in animals and man. The major side-effects of beta-blockade are heart failure and airflow obstruction. Cardiotoxicity from overdosage may be treated with isoprenaline, dopamine or glucagon while beta 2-agonists will reverse bronchoconstriction. Since beta-antagonists raise-peripheral vascular impedance, reduction of preload with nitrates enhances their antianginal efficacy. Combining a beta-antagonist with nifedipine seems especially useful. Beta-blockade is worth trying in angina with normal coronary arteries. In acute coronary insufficiency beta-blockade reduces both the work-load on the heart and the somatic features of anxiety, so preparing patients for investigations, like coronary arteriography, aimed at definitive treatment.
Insights
Beta-blockers manage angina by reducing heart workload and oxygen demand. Their precise anti-anginal effects are still explored, but they offer benefits in various cardiac conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-adrenergic antagonists (beta-blockers) competitively block beta 1-adrenoceptors, influencing myocardial contraction rate and force.
- The exact anti-anginal mechanism of beta-blockers remains uncertain, with potential roles in reducing oxygen demand and ventricular wall tension.
Purpose of the Study:
- To elucidate the mechanisms of anti-anginal action of beta-blockers.
- To review the clinical efficacy, side-effects, and therapeutic strategies involving beta-blockers.
Main Methods:
- Review of pharmacological properties including receptor antagonism, partial agonist activity, membrane stabilization, and cardioselectivity.
- Analysis of pharmacokinetic and dynamic data in animals and humans for dosage and drug selection.
- Evaluation of clinical applications, side-effects, and management of overdosage.
Main Results:
- Beta-blockers may reduce anginal pain by decreasing myocardial oxygen demand and potentially offsetting increased ventricular wall tension.
- Cardioselectivity and alpha-receptor antagonism may mitigate side effects like airflow obstruction, though clinical significance varies.
- Major side effects include heart failure and airflow obstruction; cardiotoxicity and bronchoconstriction have specific treatments.
Conclusions:
- Beta-blockade is a valuable treatment for angina, particularly in cases with normal coronary arteries and acute coronary insufficiency.
- Combining beta-blockers with nitrates or nifedipine can enhance anti-anginal efficacy.
- Beta-blockers reduce cardiac workload and anxiety, aiding in patient preparation for definitive treatments like coronary arteriography.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...